Lipid-Based Nanotechnology: Liposome
Pharmaceutics · 26.12.2023 · 16 (1) · 34
DOI: 10.3390/pharmaceutics16010034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.12.2023. Verfasst von Yanhao Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutics and Pharmacokinetics Track, Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Phar…. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, R. Ken Coit College of Pharmacy at The University of Arizona.
Abstract (Originalsprache)
Over the past several decades, liposomes have been extensively developed and used for various clinical applications such as in pharmaceutical, cosmetic, and dietetic fields, due to its versatility, biocompatibility, and biodegradability, as well as the ability to enhance the therapeutic index of free drugs. However, some challenges remain unsolved, including liposome premature leakage, manufacturing irreproducibility, and limited translation success. This article reviews various aspects of liposomes, including its advantages, major compositions, and common preparation techniques, and discusses present U.S. FDA-approved, clinical, and preclinical liposomal nanotherapeutics for treating and preventing a variety of human diseases. In addition, we summarize the significance of and challenges in liposome-enabled nanotherapeutic development and hope it provides the fundamental knowledge and concepts about liposomes and their applications and contributions in contemporary pharmaceutical advancement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaceutics and Pharmacokinetics Track, Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
- Clinical and Translational Oncology Program, NCI-Designated University of Arizona Comprehensive Cancer Center, Tucson, AZ 85721, USA.
- BIO5 Institute, The University of Arizona, Tucson, AZ 85721, USA.
- Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, AZ 85721, USA.
ORCID-Profile: Yanhao Jiang, Wenpan Li, Zhiren Wang, Jianqin Lu
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- R. Ken Coit College of Pharmacy at The University of Arizona
- PhRMA Foundation for Research Starter Grant in Drug Delivery
- National Institutes of Health (NIH)
Zitieren
APA
Jiang, Y., Li, W., Wang, Z., & Lu, J. (2023). Lipid-Based Nanotechnology: Liposome. Pharmaceutics, 16(1), 34. https://doi.org/10.3390/pharmaceutics16010034
Vancouver
Jiang Y, Li W, Wang Z, Lu J. Lipid-Based Nanotechnology: Liposome. Pharmaceutics. 2023;16(1):34. doi:10.3390/pharmaceutics16010034
BibTeX
@article{Jiang2023,
author = {Jiang, Yanhao and Li, Wenpan and Wang, Zhiren and Lu, Jianqin},
title = {Lipid-Based Nanotechnology: Liposome},
journal = {Pharmaceutics},
year = {2023},
volume = {16},
number = {1},
pages = {34},
doi = {10.3390/pharmaceutics16010034}
}
EUVIMED